WOBURN, Mass. , Oct. 01, 2019 (GLOBE NEWSWIRE) — Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced that Robert Coffin , Ph.D., Chief Executive Officer and Director of Replimune , will